SCHEMBL12765748

SCHEMBL12765748

NC1CC2CC3CC1CC(O)(C2)C3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
LMNA P02545 2/20 0.35
GRIN2D O15399 2/20 0.35
GRIN3B O60391 2/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2A Q12879 2/20 0.35
GRIN2B Q13224 2/20 0.35
GRIN2C Q14957 2/20 0.35
GRIN3A Q8TCU5 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
STAT6 P42226 1/20 0.35
SLC47A1 Q96FL8 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
HSD11B1 P28845 7/20 0.34
HSD11B2 P80365 2/20 0.34
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24658836 1.00 PKM (0.39) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL256757 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL4405412 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL974708 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL974709 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL1154281 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL2812490 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL13171860 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL3510056 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1
SCHEMBL10138542 0.81 PKM (0.37) PKMLMNAGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065762-A1 METHODS OF USE OF ANTIVIRAL COMPOUNDS INFLUMEDIX, INC. 2011-03-17 US disclosed
US-20110065762-A1 METHODS OF USE OF ANTIVIRAL COMPOUNDS INFLUMEDIX, INC. 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065762-A1 METHODS OF USE OF ANTIVIRAL COMPOUNDS MAVS, SLC30A5, HAVCR2 PKM 2637/4885LMNA 1701/4885GRIN2D 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.